OPSENS REPORTS RESULTS FOR 2016

RECORD TOTAL REVENUES DRIVEN BY TENFOLD INCREASE IN FFR SALES

Quebec City, Quebec, November 16, 2016 – Opsens Inc. (“Opsens”) (TSXV:OPS) (OTCQX:OPSSF) today reported its results for the year ended August 31, 2016.

HIGHLIGHTS

• The OptoWire II, Opsens’ guidewire to measure Fractional Flow Reserve ("FFR") has been authorized for sale in the U.S., Europe, Japan and Canada;

• FFR product sales

• FFR revenues were $2.1 million in the fourth quarter of 2016 compared with $0.3 million in the corresponding quarter of 2015;

• FFR revenues were $5.2 million for fiscal 2016 compared with $0.5 million in fiscal 2015;

• The performance of the OptoWire was highlighted in Circulation Journal, a recognized medical publication;

• Opsens extended its range of applications with 510(k) clearance from the U.S. Food and Drug Administration ("FDA") for the OptoMonitor II, a monitor combining the ability to measure FFR along with measuring intravascular and intracatheter pressure.

EXECUTING GROWTH STRATEGY

Opsens’ commercial channels are demonstrating success from quarter to quarter, with Q4 revenues up more than 600% compared with the fourth quarter of the previous year. "We are confident that the distinctive features of the OptoWire, widely recognized by key opinion leaders in interventional cardiology, will allow us to capitalize on the rapidly growing FFR market," said Louis Laflamme, President and Chief Executive Officer of Opsens.

"Our move into a modern facility and the ongoing production process improvement will enhance our competitiveness and our ability to meet the growing demand for our products. We are taking the necessary measures to become a disruptive player in the industry. For 2017, we are targeting significant gains in global market share," concluded Mr. Laflamme.

OPTOWIRE’S PERFORMANCE HIGHLIGHTED IN A MEDICAL JOURNAL

The performance of Opsens’ OptoWire was highlighted in the Circulation Journal, the official journal of the Japanese Circulation Society. The article reports that the use of approximately 100 OptoWire units was performed without any drift of the measurement and also mentions the shortcomings in the performance of competitive products in terms of reliability of the measurement.

FINANCIAL RESULTS - YEAR ENDED AUGUST 31, 2016

Opsens’ revenues were higher for the year ended August 31, 2016 at $9.6 million compared with $8.7 million in 2015. This revenue increase reflects higher revenues in FFR of $4.7 million, partly offset by a decrease of $3.4 million from non-recurring revenues recorded in 2015 from distribution rights. 

Corporate overview

Since 2003, Opsens has stood for innovative strength, a passion for technology and uncompromising commitment to quality and excellence. Pioneer in the fiber optic sensing technology, we seek to provide solutions to industries which can benefit from the advantages that our technology provides. To tap their business opportunities in both new and established markets, they organised their Company into three sectors: Medical, Energy and Industry.